Home
    Abstracts
    Registration
    Accommodation
    Contact
     Welcome Note
     Our Vision
     Committees
     Timetable
     Scientific Program
         Satellite Symposia
     Congress Presentations
     Registration
         Invitation Letter
     Accommodation
         Sheraton Roma
     Sponsors
     Sponsorship & Exhibition
     General Information
         Before you travel...
     About Rome
         Transportation
         Tips and Hints
     CME
         EHA-CME
         EACCME Certificate
         Program Evaluation
     Abstract Submission
         Poster Guidelines
         Poster Presentation
         Best Abstract Awards
     Partners
     Contact Us
The 1st World Congress on
Controversies in
Hematology (COHEM)
Rome, Italy, 2-5 September, 2010
 
  Scientific Program Print
 
Thursday, September 2, 2010
 
18:00-19:30
WELCOME RECEPTION

Friday, September 3, 2010
 
HALL A

Session 1
08:30-10:00
PLENARY SESSION 1

08:30-08:40
Opening Remarks
E. Rachmilewitz, Israel & G. Saglio, Italy

08:40-09:20 Did we substantially improve MDS therapy in the last decade?
08:40-08:45 Moderator: E. Rachmilewitz, Israel
08:45-08:55 Yes: H. Kantarjian, USA
08:55-09:05 No: C. Schiffer, USA
09:05-09:20 Discussion
 
09:20-10:00 Is there a role for SCT in Multiple Myeloma?
09:20-09:25 Moderator: J.F. San-Miguel, Spain
09:25-09:35 Yes: B. Barlogie, USA
09:35-09:45 No: M. Boccadoro, Italy
09:45-10:00 Discussion


Session 2 10:30-12:30 ACUTE MYELOID LEUKEMIA (AML) I

10:30-11:30 About targeted therapies in AML: Have standard treatments reached their limits?
10:30-10:35 Moderator: S. Amadori, Italy
10:35-10:50 Yes: A. Burnett, UK
10:50-11:05 No: B. Löwenberg, The Netherlands
11:05-11:30 Discussion

11:30-12:30 Should the therapy of AML be driven by MRD quantification?
11:30-11:35 Moderator: B. Löwenberg, The Netherlands
11:35-11:50 Yes: S. Amadori, Italy
11:50-12:05 No: C. Schiffer, USA
12:05-12:30 Discussion

12:30-13:15 Lunch Break

CURRENT PROGRESS IN CML THERAPY
13:15 - 14:30
Satellite Symposium by Novartis

Chairpersons:
M. Baccarani, Italy
R. Hehlmann, Germany
13:15-13:20 Welcome
13:20-13:35
Molecular Monitoring of CML: Progress in standardization
F. Pane, Italy
13:35-13:45 Discussion
13:45-14:00
Second generation TKIs as first-line therapy: ENESTnd
A. Hochhaus, Germany
14:00-14:10 Discussion
14:10-14:25
Nilotinib: A selective choice for resistant and Intolerant patients to Imatinib
M. Breccia, Italy
14:25-14:30 Closing


Session 3
14:30-16:00
ACUTE MYELOID LEUKEMIA (AML) II and
ACUTE PROMYELOCYTIC LEUKEMIA (APL)

14:30-15:15 Do we require chemotherapy to cure APL?
14:30-14:35 Moderator: A. Burnett, UK
14:35-14:45 Yes: M.A. Sanz, Spain
14:45-14:55 No: F. Lo-Coco, Italy
14:55-15:15 Discussion

15:15-16:00 Can novel prognostic markers predict for success and guide therapy in AML?
15:15-15:20 Moderator: C. Schiffer, USA
15:20-15:30 Yes: D. Grimwade, UK
15:30-15:40 No: A. Burnett, UK
15:40-16:00 Discussion

 

16:00-16:10       Best Abstract Awards Ceremony



Session 4
16:30-18:00
ACUTE LYMPHATIC LEUKEMIA (ALL)

16:30-17:15 Is the efficacy of the pediatric-like protocols for ALL superior to the protocols for adult ALL?
16:30-16:35 Moderator: R. Foà, Italy
16:35-16:45 Yes: J.P. Marie, France
16:45-16:55 No: J. Ribera, Spain
16:55-17:15 Discussion

17:15-18:00 Should the induction for Ph+ ALL be based on TKI alone or TKI plus chemotherapy?
17:15-17:20 Moderator: J.P. Marie, France
17:20-17:30 TKI alone: R. Foà, Italy
17:30-17:40 TKI plus chemotherapy: O. Ottmann, Germany
17:40-18:00 Discussion

HALL B

Session 5
10:30-12:30
CHRONIC LYMPHATIC LEUKEMIA (CLL)

10:30-11:30 Is eradication of MRD feasible and worthwhile in CLL?
10:30-10:35 Moderator: K. Rai, USA
10:35-10:50 Yes: G. Marti, USA
10:50-11:05 No: G. Gaidano, Italy
11:05-11:30 Discussion

11:30-12:30 Is the “wait and watch” philosophy still practical in the treatment of CLL even in younger patients?
11:30-11:35 Moderator: A. Polliack, Israel
11:35-11:50 Yes: K. Rai, USA
11:50-12:05 No: F. Caligaris-Cappio, Italy
12:05-12:30 Discussion

12:30-13:15 Lunch Break


Session 6
14:30-16:00
INDOLENT NON-HODGKIN LYMPHOMA (NHL)

14:30-15:15 Is there a role for Rituximab in maintenance treatment in non-follicular indolent lymphomas?
14:30-14:35 Moderator: C. Portlock, USA
14:35-14:45 Yes: A. Hagenbeek, The Netherlands
14:45-14:55 No: C. Buske, Germany
14:55-15:15 Discussion

15:15-16:00 Is molecular remission the goal in first line therapy of all patients with indolent non-Hodgkin lymphoma?
15:15-15:20 Moderator: A. Hagenbeek, The Netherlands
15:20-15:30 Yes: P. Corradini, Italy
15:30-15:40 No: C. Tarella, Italy
15:40-16:00 Discussion


Session 7
16:30-18:00
MULTIPLE MYELOMA (MM)

16:30-17:15 Multiple Myeloma in patients < 70 years: Cure vs. disease control
16:30-16:35 Moderator: N. Kröger, Germany
16:35-16:45 Cure: J.F. San-Miguel, Spain
16:45-16:55 Control: M. Boccadoro, Italy
16:55-17:15 Discussion

17:15-18:00 Should therapy for newly diagnosed MM be risk adapted?
17:15-17:20 Moderator: M. Boccadoro, Italy
17:20-17:30 Yes: B. Barlogie, USA
17:30-17:40 No: E. Terpos, Greece
17:40-18:00 Discussion

Saturday, September 4, 2010

HALL A

Session 8
08:30-10:00
STEM CELL TRANSPLANTATION (SCT) I
The role of Allogeneic SCT (AlloSCT) in Hematological Malignancies

08:30-09:15 How should we treat a 60 year old patient with Myelodysplastic syndrome?
08:30-08:35 Moderator: M. Martelli, Italy
08:35-08:45 AlloSCT: N. Kröger, Germany
08:45-08:55 Conventional Therapy: U. Platzbecker, Germany
08:55-09:15 Discussion

09:15-10:00 Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients?
09:15-09:20 Moderator: W. Arcese, Italy
09:20-09:30 All: A. Goldstone, UK
09:30-09:40 Only high risk: D. Hoelzer, Germany
09:40-10:00 Discussion


Session 9
10:30-12:30
STEM CELL TRANSPLANTATION (SCT) II
Alternative Donor and Reduced Intensity Conditioning (RIC) AlloSCT

10:30-11:40 Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available?
10:30-10:35 Moderator: A. Rambaldi, Italy
10:35-10:50 CBT: W. Arcese, Italy
10:50-11:05 Haplo: M. Martelli, Italy
11:05-11:20 MUD: A. Bacigalupo, Italy
11:20-11:40 Discussion

11:40-12:30 Should we use AlloSCT in Acute Myeloid Leukemia RIC or Myeloablative preparative protocols?
11:40-11:45 Moderator: A. Bacigalupo, Italy
11:45-12:00 RIC: A. Nagler, Israel
12:00-12:15 Myeloablative: A. Rambaldi, Italy
12:15-12:30 Discussion

12:30-13:15 Lunch Break

POTENTIAL NEW STRATEGIES FOR FIRST-LINE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA 
13:15 - 14:30
Satellite Symposium by Bristol-Myers Squibb / Otsuka

13:15-13:20 Welcome And Outline Of Program
M. Baccarani, Italy
13:20-13:40
Why Is There A Need To Optimize first-Line Treatment Of CML-CP?
A. Hochhaus, Germany
13:40-14:00 Can New Investigational Strategies Help Optimize Treatment For Newly Diagnosed CML-CP Patients?
M. Baccarani, Italy
 14:00-14:20
Perspectives On Strategies For First-Line Treatment Of CML-CP
G. Saglio, Italy
14:20-14:30 Panel Discussion And Audience Questions
Moderator: M. Baccarani, Italy


Session 10
14:30-16:00
MDS

14:30-15:15 Do hypomethylating agents improve survival in patients with high risk myelodysplastic syndromes?
14:30-14:35 Moderator: G. Leone, Italy
14:35-14:45 Yes: V. Santini, Italy
14:45-14:55 No: M. Cazzola, Italy
14:55-15:15 Discussion

15:15-16:00 Is there a rationale for iron chelation therapy in MDS?
15:15-15:20 Moderator: E. Rachmilewitz, Israel
15:20-15:30 Yes: N. Gattermann, Germany
15:30-15:40 No: A. Tefferi, USA
15:40-16:00 Discussion


Session 11
16:30-18:00
HODGKIN AND NON-HODGKIN LYMPHOMA

16:30-17:15 Has PET/CT an established role in the management of HD and NHLs?
16:30-16:35 Moderator: M. Björkholm, Sweden
16:35-16:45 Yes: M. Hutchings, Denmark
16:45-16:55 No: U. Vitolo, Italy
16:55-17:15 Discussion

17:15-18:00 Does molecular outcome prediction in DLBCL add clinical value?
17:15-17:20 Moderator: M. Björkholm, Sweden
17:20-17:30 Yes: C. Gisselbrecht, France
17:30-17:40 No: M. Pfreundschuh, Germany
17:40-18:00 Discussion

HALL B

Session 12
08:30-10:00
COAGULATION
 
08:30-09:15 Are there indications for thrombophylaxis in cancer patients during and after chemotherapy?
08:30-08:35 Moderator: M.M. Samama, France
08:35-08:45 Yes: A. Falanga, Italy
08:45-08:55 No: A. Kakkar, UK
08:55-09:15 Discussion

09:15-10:00 Is there still a role for splenectomy in ITP?
09:15-09:20 Moderator: A. Falanga, Italy
09:20-09:30 Yes: B. Godeau, France
09:30-09:40 No: J. Bussel, USA
09:40-10:00 Discussion


Session 13
10:30-12:30
CHRONIC MYELOID LEUKEMIA (CML) I

10:30-11:10 Is mutation analysis of BCR ABL of any value in clinical management of CML patients?
10:30-10:35 Moderator: J. Goldman, UK
10:35-10:45 Yes: A. Hochhaus, Germany
10:45-10:55 No: D. Marin, UK
10:55-11:10 Discussion

11:10-11:50 Should first line imatinib treatment be optimized by combination with IFN or by higher imatinib dose?
11:10-11:15 Moderator: A. Hochhaus, Germany
11:15-11:25 Combination with IFN: F. Guilhot, France
11:25-11:35 Higher initial imatinib dose: R. Hehlmann, Germany
11:35-11:50 Discussion

11:50-12:30 On the road to cure CML, does it matter to hit different pathways?
11:50-11:55 Moderator: R. Hehlmann, Germany
11:55-12:05 Yes: N. Shah, USA
12:05-12:15 No: G. Saglio, Italy
12:15-12:30 Discussion

12:30-13:15 Lunch Break


Session 14
14:30-16:00
CHRONIC MYELOID LEUKEMIA (CML) II

14:30-15:15 Will second generation TKIs substitute imatinib as first line treatment of CML?
14:30-14:35 Moderator: R. Hehlmann, Germany
14:35-14:45 Yes: M. Baccarani, Italy
14:45-14:55 No: H. Kantarjian, USA
14:55-15:15 Discussion
 
15:15-16:00 Can we eventually stop TKI in all CML patients?
15:15-15:20 Moderator: M. Baccarani, Italy
15:20-15:30 Yes: F. Mahon, France
15:30-15:40 No: J. Goldman, UK
15:40-16:00 Discussion


Session 15
16:30-18:30
HEMOGLOBINOPATHIES & PNH

16:30-16:50 Pros and cons of gene therapy in beta-thalassemia
16:30-16:35 Moderator: L. Luzzatto, Italy
16:35-16:50 Lecture: S. Rivella, USA

16:50-17:10 The controversies in the use of chelating drugs for the treatment of iron overload affect the morbidity and mortality of thalassaemia and other transfused patients worldwide
16:50-16:55 Moderator: E. Rachmilewitz, Israel
16:55-17:10 Lecture: G. Kontoghiorghes, Cyprus

17:10-17:50 How far one should go with iron chelation in thalassemia? Is iron deficiency indicated?
17:10-17:15 Moderator: E. Rachmilewitz, Israel
17:15-17:25 Yes: V. Berdoukas, Greece
17:25-17:35 No: M.D. Cappellini, Italy
17:35-17:50 Discussion

17:50-18:30 Do the benefits of complement blockade extend to all patients with PNH clone?
17:50-17:55 Moderator: M.D. Cappellini, Italy
17:55-18:05 Yes: A.M. Risitano, Italy
18:05-18:15 No: L. Luzzatto, Italy
18:15-18:30 Discussion

Sunday, September 5, 2010

HALL A

Session 16
08:30-10:00
MYELO PROLIFERATIVE NEOPLAMS (MPNs)

08:30-09:15 Are JAK2 positive PV, ET and IM different diseases?
08:30-08:35 Moderator: A. Tefferi, USA
08:35-08:45 Yes: W. Vainchenker, France
08:45-08:55 No: A.M. Vannucchi, Italy
08:55-09:15 Discussion

09:15-10:00 Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferative neoplasms?
09:15-09:20 Moderator: W. Vainchenker, France
09:20-09:30 Yes: A. Tefferi, USA
09:30-09:40 No: T. Barbui, Italy
09:40-10:00 Discussion

HALL B

Session 17
08:30-10:00
INFECTIONS

08:30-09:15 Is there a role for empirical or pre-emptive antifungal treatment in patients with hematological malignancies?
08:30-08:35 Moderator: F. Menichetti, Italy
08:35-08:45 Yes: B. de Pauw, The Netherlands
08:45-08:55 No: A. Prentice, UK
08:55-09:15 Discussion

09:15-10:00 Is monitoring of azole concentrations of clinical value in pts with hematological malignancies?
09:15-09:20 Moderator: B. de Pauw, The Netherlands
09:20-09:30 Yes: F. Menichetti, Italy
09:30-09:40 No: P. Donnelly, The Netherlands
09:40-10:00 Discussion

HALL A

Session 18
10:30-12:30
PLENARY SESSION 18

10:30-11:05 Is there a role of biologic prognostic markers in the treatment of CLL?
10:30-10:35 Moderator: E. Rachmilewitz, Israel
10:35-10:45 For: R. Foà, Italy
10:45-11:55 Against: K. Rai, USA
11:55-11:05 Discussion

11:05-11:40 Are there sufficient indications for switching to new anticoagulant agents?
11:05-11:10 Moderator: G. Saglio, Italy
11:10-11:20 For: M.M. Samama, France
11:20-11:30 Against: A. Falanga, Italy
11:30-11:40 Discussion

11:40-12:15 Which is the best chemotherapy regimen in Hodgkin Lymphoma?
11:40-11:45 Moderator: D. Straus, USA
11:45-11:55 ABVD: A. Levis, Italy
11:55-12:05 BEACOPP: V. Diehl, Germany
12:05-12:15 Discussion

12:15-12:30 Is chemotherapy alone sufficient for the treatment of Hodgkin Lymphoma?
12:15-12:30 Lecture: D. Straus, USA

Home    Registration    Accommodation    Contact Us   
Copyright © 2007 Comtecmed.com. All rights reserved.   The website was last updated on 07/04/2013 Created by    WebStudio.co.il